|
1
|
Messerschmitt PJ, Garcia RM, Abdul-Karim
FW, Greenfield EM and Getty PJ: Osteosarcoma. J Am Acad Orthop
Surg. 17:515–527. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the surveillance, epidemiology, and end results program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bacci G, Rocca M, Salone M, Balladelli A,
Ferrari S, Palmerini E, Forni C and Briccoli A: High grade
osteosarcoma of the extremities with lung metastases at
presentation: Treatment with neoadjuvant chemotherapy and
simultaneous resection of primary and metastatic lesions. J Surg
Oncol. 98:415–420. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bielack SS, Carrle D, Hardes J, Schuck A
and Paulussen M: Bone tumors in adolescents and young adults. Curr
Treat Options Oncol. 9:67–80. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hughes DP: Strategies for the targeted
delivery of therapeutics for osteosarcoma. Expert Opin Drug Deliv.
6:1311–1321. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ferrari S, Smeland S, Mercuri M, Bertoni
F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini
G, et al: Neoadjuvant chemotherapy with high-dose ifosfamide,
high-dose methotrexate, cisplatin, and doxorubicin for patients
with localized osteosarcoma of the extremity: A joint study by the
Italian and Scandinavian sarcoma groups. J Clin Oncol.
23:8845–8852. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mialou V, Philip T, Kalifa C, Perol D,
Gentet JC, Marec-Berard P, Pacquement H, Chastagner P, Defaschelles
AS and Hartmann O: Metastatic osteosarcoma at diagnosis: Prognostic
factors and long-term outcome-the French pediatric experience.
Cancer. 104:1100–1109. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Smeland S, Müller C, Alvegard TA, Wiklund
T, Wiebe T, Björk O, Stenwig AE, Willén H, Holmström T, Follerås G,
et al: Scandinavian sarcoma group osteosarcoma study SSG VIII:
Prognostic factors for outcome and the role of replacement salvage
chemotherapy for poor histological responders. Eur J Cancer.
39:488–494. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Klugbauer S and Rabes HM: The
transcription coactivator HTIF1 and a related protein are fused to
the RET receptor tyrosine kinase in childhood papillary thyroid
carcinomas. Oncogene. 18:4388–4393. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hatakeyama S: TRIM proteins and cancer.
Nat Rev Cancer. 11:792–804. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
de Thé H, Lavau C, Marchio A, Chomienne C,
Degos L and Dejean A: The PML-RAR alpha fusion mRNA generated by
the t (15;17) translocation in acute promyelocytic leukemia encodes
a functionally altered RAR. Cell. 66:675–684. 1991. View Article : Google Scholar
|
|
12
|
Cambiaghi V, Giuliani V, Lombardi S,
Marinelli C, Toffalorio F and Pelicci PG: TRIM proteins in cancer.
Adv Exp Med Biol. 770:77–91. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Le Douarin B, Zechel C, Garnier JM, Lutz
Y, Tora L, Pierrat B, Heery D, Gronemeyer H, Chambon P and Losson
R: The N-terminal part of TIF1, a putative mediator of the
ligand-dependent activation function (AF-2) of nuclear receptors,
is fused to B-raf in the oncogenic protein T18. EMBO J.
14:2020–2033. 1995.PubMed/NCBI
|
|
14
|
Zhou Z, Ji Z, Wang Y, Li J, Cao H, Zhu HH
and Gao WQ: TRIM59 Is up-regulated in gastric tumors, promoting
ubiquitination and degradation of p53. Gastroenterology.
147:1043–1054. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Valiyeva F, Jiang F, Elmaadawi A, Moussa
M, Yee SP, Raptis L, Izawa JI, Yang BB, Greenberg NM, Wang F and
Xuan JW: Characterization of the oncogenic activity of the novel
TRIM59 gene in mouse cancer models. Mol Cancer Ther. 10:1229–1240.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Khatamianfar V, Valiyeva F, Rennie PS, Lu
WY, Yang BB, Bauman GS, Moussa M and Xuan JW: TRIM59, a novel
multiple cancer biomarker for immunohistochemical detection of
tumorigenesis. BMJ Open. 2:pii.e0014102012. View Article : Google Scholar
|
|
17
|
Valiyeva F, Jiang F, Elmaadawi A, Moussa
M, Yee SP, Raptis L, Izawa JI, Yang BB, Greenberg NM, Wang F and
Xuan JW: Characterization of the oncogenic activity of the novel
TRIM59 gene in mouse cancer models. Mol Cancer Ther. 10:1229–1240.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mavinahalli JN, Madhumalar A, Beuerman RW,
Lane DP and Verma C: Differences in the transactivation domains of
p53 family members: A computational study. BMC Genomics. 11(Suppl
1): S52010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Muller PA and Vousden KH: Mutant p53 in
cancer: New functions and therapeutic opportunities. Cancer Cell.
25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sauer M, Bretz AC, Beinoraviciute-Kellner
R, Beitzinger M, Burek C, Rosenwald A, Harms GS and Stiewe T:
C-terminal diversity within the p53 family accounts for differences
in DNA binding and transcriptional activity. Nucleic Acids Res.
36:1900–1912. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kussie PH, Gorina S, Marechal V, Elenbaas
B, Moreau J, Levine AJ and Pavletich NP: Structure of the MDM2
onco-protein bound to the p53 tumor suppressor transactivation
domain. Science. 274:948–953. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Momand J, Zambetti GP, Olson DC, George D
and Levine AJ: The mdm-2 oncogene product forms a complex with the
p53 protein and inhibits p53-mediated transactivation. Cell.
69:1237–1245. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Overholtzer M, Rao PH, Favis R, Lu XY,
Elowitz MB, Barany F, Ladanyi M, Gorlick R and Levine AJ: The
presence of p53 mutations in human osteosarcomas correlates with
high levels of genomic instability. Proc Natl Acad Sci USA.
100:11547–11552. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Marina N, Gebhardt M, Teot L and Gorlick
R: Biology and therapeutic advances for pediatric osteosarcoma.
Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sandberg AA and Bridge JA: Updates on the
cytoge-netics and molecular genetics of bone and soft tissue
tumors: Osteosarcoma and related tumors. Cancer Genet Cytogenet.
145:1–30. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ottaviani G and Jaffe N: The etiology of
osteosarcoma. Cancer Treat Res. 152:15–32. 2009. View Article : Google Scholar
|
|
27
|
Kim FM, Hayes C, Williams PL, Whitford GM,
Joshipura KJ, Hoover RN and Douglass CW; National Osteosarcoma
Etiology Group: An assessment of bone fluoride and osteosarcoma. J
Dent Res. 90:1171–1176. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kondo T, Watanabe M and Hatakeyama S:
TRIM59 interacts with ECSIT and negatively regulates NF-kB and
IRF-3/7-mediated signal pathways. Biochem Biophys Res Commun.
422:501–507. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vousden KH and Prives C: Blinded by the
light: The growing complexity of p53. Cell. 137:413–431. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pei D, Zhang Y and Zheng J: Regulation of
p53: A collaboration between Mdm2 and Mdmx. Oncotarget. 3:228–235.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang X and Jiang X: Mdm2 and MdmX partner
to regulate p53. FEBS Lett. 586:1390–1396. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shvarts A, Steegenga WT, Riteco N, van
Laar T, Dekker P, Bazuine M, van Ham RC, van der Houven van Oordt
W, Hateboer G, van der Eb AJ and Jochemsen AG: MDMX: A novel
p53-binding protein with some functional properties of MDM2. EMBO
J. 15:5349–5357. 1996.PubMed/NCBI
|
|
33
|
Danovi D, Meulmeester E, Pasini D,
Migliorini D, Capra M, Frenk R, de Graaf P, Francoz S, Gasparini P,
Gobbi A, et al: Amplification of Mdmx (or Mdm4) directly
contributes to tumor formation by inhibiting p53 tumor suppressor
activity. Mol Cell Biol. 24:5835–5843. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zdzalik M, Pustelny K, Kedracka-Krok S,
Huben K, Pecak A, Wladyka B, Jankowski S, Dubin A, Potempa J and
Dubin G: Interaction of regulators Mdm2 and Mdmx with transcription
factors p53, p63 and p73. Cell Cycle. 9:4584–4591. 2010. View Article : Google Scholar : PubMed/NCBI
|
